Framing: resolve product eligibility independently of the facility’s registration. FDA’s 503B materials describe separate restrictions on using bulk drug substances: the relevant substance must qualify through the bulks-list route or the drug must meet the shortage-list condition at compounding, distribution and dispensing. (fda.gov)
Put to: Jesse Dresser and Michael Ganio.
Buyer owner: Counsel, medical director and procurement.
Why it matters: The buyer must not interpret ‘503B’ as permission to purchase any proposed GLP-1 preparation as clinic stock.
A good answer should cover:
- Whether the preparation starts from bulk API or an approved finished product, and why that distinction matters to the analysis.
- Each applicable product, copying, distribution and state-law condition—not merely the facility category.
- The difference between patient-specific dispensing, office administration and onward distribution.
- How the supplier’s argument addresses FDA’s published bulks restrictions and the April 2026 proposal, without treating a proposal as a newly effective rule. (fda.gov)
Follow-up that tests the answer: “If you removed the registration certificate from this pack, what product-specific evidence would still support the proposed transaction?”
Evidence to request: A written, dated legal analysis identifying preparation, ingredients, facility, destination, transaction and unresolved issues. Do not issue a purchase order while a material eligibility question remains unresolved.
Expert quote — reserved: ________________________________________
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
- fda.gov · Source 2 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list